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Abstract
Obesity develops when energy intake exceeds energy expenditure. Defect in the
function of brown fat and skeletal muscle, two of the major tissues that contribute
towards energy expenditure, lead to the development of obesity and metabolic
syndrome. Our previous findings suggest that Tyk2 deficient mice become obese and
develop the metabolic syndrome. Tyk2, which is a tyrosine kinase of the JAK-STAT
signaling family, is important for optimal brown development and function. Since brown
fat and skeletal muscle, both are derived from the Myf5+ lineage of mesenchymal stem
cells, we also characterized the role of Tyk2 in the development and function of skeletal
muscle. We found that Tyk2 deficient mice do not display a structural defect in skeletal
muscle development; however, the function of skeletal muscle is severely impaired in
these mice. Expression of troponins, which regulate the muscle contraction and muscle
creatine kinase, which regulates the levels of phosphocreatine, a major fuel for skeletal
muscle, is downregulated in Tyk2 deficient mice. Skeletal muscle mitochondria also
display an abnormal morphology along with decreased respiration capacity, which is a
function of decreased activity of complex IV of the electron transport chain. Interestingly,
Tyk2 deficient mice also exhibit an increased proportion of fast, glycolytic, Type II fibers
in the skeletal muscle. Using an in-vitro system for skeletal muscle differentiation, we
found that Tyk2 levels increase during differentiation, suggesting a role for Tyk2 in
proper development and function of the skeletal muscle.
Our previous studies suggested that a kinase-inactive (Tyk2KD) form of Tyk2 is also
efficient in restoring the function of Tyk2 deficient brown fat preadipocytes. We
generated transgenic mice that expressed a wild type (Tyk2WT) and kinase inactive

(Tyk2 KD) form of tyk2 in brown fat and skeletal muscle under Myf5 cre and in skeletal
muscle using MCK cre mice. Expression of Tyk2 using the Myf5 cre (E8.0) reverts the
obese and the metabolic phenotype observed in the Tyk2 deficient mice. Interestingly,
expressing Tyk2 under MCK cre (E13.0) also reverts the obese phenotype, suggesting
that the temporal and spatial expression of Tyk2 is critical in regulating energy
expenditure.
Our studies also highlight the role of Tyk2, not as a kinase, but as a component of the
transcriptional assembly regulating the expression of genes involved brown fat and
skeletal muscle differentiation and function.

Chapter I: Introduction
Obesity is a global phenomenon affecting at least 200 billion adults to date. In the
United States alone, over a third of the population is obese. Obesity in children and
adolescents has also increased from 5% in the 1980s to 18% in 2012. Obesity is usually
defined by the body mass index (BMI; weight in kilograms divided by length in squared
meters, kg/m2). A BMI >25 kg/m2 represents overweight, >30 kg/m2 obese and >40
kg/m2 morbidly obese individuals (1). Incidence of Type II diabetes is also linked to
obesity. As such, the world health organization (WHO) estimates that the number of
diabetics will reach around 300 billion in 2025 (2).
Obesity is a result of increased energy intake and/or decreased energy expenditure.
This excess weight is stored in adipose tissue, which consists of fat cells, or adipocytes,
which have an incredible capacity for storing surplus energy in the form of lipid (3).
Obesity is also associated with many abnormalities collectively known as the metabolic
syndrome, including dyslipidemia, increased risk for cardiovascular disease, and
abnormal glucose metabolism. All of these alterations can easily factor into the
development of insulin resistance and type II diabetes (4).
Changing diet and lifestyle are the common treatments suggested for obesity, however,
in morbidly obese patients, bariatric surgery has been the only effective treatment to
date (1). Currently, there are drugs that aim at decreasing energy intake by acting on
the satiety centers in the brain. Nonetheless, decreasing food intake is known to trigger
the starvation response in mammals and hence these treatments become ineffective
after a while (5). Developing alternative therapies that will enhance energy expenditure
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in obese individuals is the need of the hour. Mammals have two major thermogenic
tissues- Brown Adipose Tissue (BAT) and Skeletal Muscle (SKM), which are involved in
regulation of energy expenditure. Increasing the thermogenic capacities of these tissues
and hence increasing overall energy expenditure may provide an alternative means of
combating obesity.

1.1: Brown Adipose Tissue in obesity
Mammals have two functionally different types of adipose tissues- white adipose tissue
(WAT) and brown adipose tissue (BAT). WAT mainly functions as an energy store
whereas the main function of BAT is to dissipate energy in the form of heat (6).
Differences between BAT and WAT are listed in Table 1.1. In rodents BAT is present
throughout life. Major depots are located primarily in the interscapular region and the
axillae, whereas minor amounts exist near the thymus and in the dorsal midline region
of the thorax and abdomen. The activity of BAT in non- hibernating animals is strictly
related to the environmental temperature with cold exposure inducing its action. In
neonates and hibernating animals, BAT serves as an important regulator of the body
temperature via non- shivering thermogenesis.
Studies on rodent models suggest that BAT also plays an important role in prevention of
obesity. Transgenic mice with ablated BAT exhibit metabolic syndrome (7). Uncoupling
protein 1 (UCP1) is unique to brown fat and is responsible for dissipating the
mitochondrial proton gradient, thus releasing this potential energy as heat. UCP1 null
mice exhibit an obese phenotype (8). Additional examples of the relevance of BAT
against the development of obesity come from genetically obese mouse models like the
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ob/ob and db/db strains where BAT is dysfunctional (9). BAT activity is also lower in
overweight and obese individuals compared to the lean individuals. Whereas BMI and
body fat percentage showed an inverse correlation with BAT activity, resting metabolic
rate exhibited a positive correlation with BAT activity. Interestingly, it has been observed
that higher levels of BAT might protect against age-related obesity (6).
The presence of active brown fat depots in human newborns and its role in nonshivering thermogenesis has been well studied. However little was known about the
presence of active brown fat depots in adult humans. It was a well-conceived notion that
brown adipose tissue is rapidly lost postnatally, within the first (few) years of life, and
that older adults do not possess more than vestigial amounts of brown adipose tissue
(10).
The recent discovery with the use of fluorodeoxyglucose positron emission tomography
(FDG PET) suggested that adult humans possess active brown fat depots (10) has
sparked a renewed interest in using brown fat thermogenesis as a treatment for obesity.
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Table 1.1: Differences between WAT and BAT (adapted from (11))

Function

WAT

BAT

Energy storage in form of fatty

Heat production, thermogenesis,

acids, triglycerides, secretion of

low fat storage capacity

adipokines

Subcutaneous, abdominal,

Intrascapular,

paravertebral,

Location
perirenal, gonadal

Sympathetic and parasympathetic

axillary and perineal

Sympathetic

innervation,

Macroscopic
innervation, small lobules of

Lobular organization with gland-

Features
densely packed cells

like structure

Multilocular, small lipid droplets,
Microscopic

One single large droplet, few,
abundant,

Features

small elongated mitochondria
mitochondria
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large,

round

1.1.1: Development of brown fat
Brown adipose tissue (BAT), a unique organ to mammals, is developed in the later
stages of embryonic development (12). Its major function is dissipation of energy as
heat, for defense against cold (12, 13). Brown fat, is developed from the Myf5+ lineage
of mesenchymal stem cells (14), Myf5 is one of the earliest myogenic factors to be
expressed and determines the myogenic lineage (15). Brown fat, hence, is a close
relative of skeletal muscle than white adipose tissue (WAT). Functionally, WAT and BAT
carry entirely different functions, the major function of WAT being storage of energy
whereas of BAT being dissipation of energy as heat. Although, WAT and BAT share
some common adipogenic factors in development, BAT development occurs early in
embryogenesis, whereas it is not until after birth that WAT depots are developed (13).
Let’s take a quick look at some of the transcription factors important for BAT
development.
a) C/EBP and PPARs
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription
factors belonging to the nuclear receptor superfamily. The three known subtypes
PPARα, PPARγ and PPARδ have different tissue distributions and play a key role as
regulators of glucose and lipid homeostasis as well as in cell proliferation, differentiation
and inflammatory responses (16). PPARγ plays a central role in differentiation of both
brown and white adipocytes (17). The C/EBP (CCAAT/enhancer-binding proteins)
family consists of 6 members- C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, C/EBPε and
C/EBPζ (18). Of the C/EBP family, C/EBPα and C/EBPβ were identified as key
transcription factors driving fat cell differentiation (18). C/EBPs function cooperatively
7

with PPARγ and promote a transcriptional cascade that promotes and maintains the
stable differentiated state of adipocytes (19). Interestingly, ectopic expression of
C/EBPβ in white fat cells has been shown to promote the expression of BAT selective
genes (17).
b) PGC1α
PPARγ coactivator 1α (PGC1α) was identified from brown fat cells as a cold-inducible
coactivator of PPARγ and other nuclear hormone receptors (20). PGC1α is an important
regulator of mitochondrial biogenesis (21) and plays an important role in regulating the
function of mitochondria-rich BAT. Ectopic expression of PGC1α in white adipocytes
has been shown to induce the expression of UCP1 and promote differentiation toward
the brown fat phenotype (22). Despite its importance in the thermogenic function of
BAT, PGC1α still remains dispensable for differentiation of BAT.
c) PRDM16
PRD1-BF1-RIZ1-containing homologous domain containing protein 16 (PRDM16) was
identified in a screen that involved determining the transcriptional factors selectively
expressed in BAT (23). PRDM16 is highly enriched in BAT as compared to WAT and
when ectopically expressed in white preadipocytes and fibroblasts, it can initiate
complete brown fat differentiation. Expression of PRDM16 is not induced during cold
exposure, suggesting that it is only acting as a brown fat determinant and not in its
function. Interestingly, mutating the DNA binding residue in PRDM16 does not alter its
ability to initiate brown fat differentiation nor its interaction with PGC1α, suggesting that
PRDM16 acts in a transcriptional complex to regulate brown fat determination (23).
Knockdown of PRDM16 in brown adipocytes induces the expression of skeletal muscle
8

specific genes like MCK, MyoD and Myogenin, suggesting that PRDM16 may also act
as a Myf5+ lineage specific determinant (24).

1.1.2: Brown fat in Thermogenesis
Brown fat is mainly involved in maintaining the body temperature via nonshivering
thermogenesis. Nonshivering thermogenesis is independent of shivering, which occurs
in the skeletal muscle. Studies from the 1950s demonstrated that following
norepinephrine injection, there was an increase in BAT thermogenesis. Recent studies
have shown that cold induced adaptive thermogenesis is UCP1 dependent and requires
activation of the sympathetic nervous system, of which norepinephrine is the primary
signaling component (25). Cold induced responses can also be mimicked by injecting
mice with norepinephrine. The hypothalamus motor neurons senses any changes in
temperature and activates the sympathetic nervous system. Thermogenesis in BAT is
activated by the nor-epinephrine released by the sympathetic nervous system, mainly
by activation of the β3 adrenergic receptors. This leads to an increase in intracellular
cAMP concentration, downstream of the G-protein coupled β3 adrenergic receptors and
thus activation of PKA, which triggers lipolysis. Increased lipolysis lead to an increased
cellular concentration of free fatty acids which are transported to mitochondria, leading
to the activation of mitochondrial electron transport chain and the mitochondrial
uncoupling protein UCP1 (26).
The mitochondrial electron transport chain (ETC) consists of a series of four complexes
(Complex I-IV) and electron carriers (coenzyme Q,cytochrome c). The flow of electrons
via these complexes pumps protons across the inner mitochondrial membrane, thus
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generating a proton gradient across the inner mitochondrial membrane. The proton
gradient then drives the synthesis of ATP as protons flow passively back into the
mitochondrial matrix through a pore that is associated with ATP synthase (or complex
V) to generate ATP from ADP and Pi.
The uncoupling proteins (UCPs) belong to a class of mitochondrial transporter proteins,
spanning across the inner mitochondrial membrane. Similar to other mitochondrial
proton channels like Adenine nucleotide transporter (ANT), UCP1 increases the
permeability of the inner mitochondrial membrane, allowing the passage of protons
against the gradient back into the mitochondrial matrix. This releases the stored
potential energy and is lost as heat, rather than being converted into chemical energy in
form of ATP by mitochondrial ATP synthase. UCP1 is primarily expressed in the brown
fat, whereas UCP2 exhibits a global tissue distribution. UCP3 is restricted to the skeletal
muscle. Besides UCP1, the role of other UCPs in uncoupling mitochondrial ETC from
oxidative phosphorylation is not well characterized (27). BAT heavily relies on the
mitochondrial uncouplers for generation of heat.
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Figure 1.1: UCP1 along with mitochondrial electron transport chain: Mitochondrial
oxidative phosphorylation begins with the entry of electrons into the ETC, which is
impermeable to low-molecular-weight solutes. Electrons flow through the four
membrane bound complexes (Complex I-IV) with the aid of the electron carriers. The
transfer of the electrons generates a membrane potential (ΔΨm) across the inner
mitochondrial membrane. UCP1 dissipates this proton gradient, thus releasing the
potential energy as heat. (Modified from (28)).
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Figure 1.2: Norepinephrine mediated activation of non-shivering thermogenesis
in brown fat. Thermogenesis occurs in brown adipocytes with the stimulation of βadrenergic receptors (βARs), initiating a signal transduction cascade that produces
cyclic AMP (cAMP) and activates protein kinase A (PKA), which then activates multiple
enzymes responsible for converting the catabolic end products of macronutrients
(carbohydrates, fats (triacylglycerols (TAG) and free fatty acids (FFA)) and proteins) into
mitochondrial fuel. The electrons generated by the TCA cycle feed into the electron
transport chain, generating a proton gradient, which is dissipated by UCP1 and heat is
generated in this process (5).
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1.2: Skeletal Muscle in obesity
Skeletal muscle is an important metabolic tissue in mammals. In humans, SKM
comprises roughly 30-50% of the body mass and handles almost 80-95% of insulin
mediated glucose uptake (29). Impaired glucose uptake and decreased oxidative
capacity of skeletal muscle is one of the major contributors toward the pathophysiology
of obesity and metabolic syndrome. Skeletal-muscle is also a non-adipose site for lipid
accumulation (29) and plays an important role in fatty acid oxidation thereby controlling
circulating lipid levels (30). Obesity and metabolic syndrome are correlated with the
level of physical activity as well as the accumulation of intramyocellular lipids and fatty
acid oxidation in SKM (30). Skeletal muscles are also specialized to dissipate energy
directly as heat (figure 1.4) in response to external stimuli and hence important in
energy expenditure (5). These studies suggest that a defect in SKM plays a significant
role in the pathogenesis of obesity and metabolic syndrome.

1.2.1: Structure of Skeletal Muscle
Skeletal muscle, along with heart, is an important contractile tissue in mammals. The
smallest contractile unit of skeletal muscle is termed as a sarcomere. A sarcomere
consists of an assembly of thick filaments (myosin heavy and light chains) and thin
filaments (actin) inserted between two z-discs and an M line running through the center
(Figure 1.3). A complex of Troponins (Troponin T, Troponin I and Troponin C) and
Tropomyosins sit on the thin filaments (31, 32).
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Figure 1.3: Structure of skeletal muscle: Sarcomeric assembly consists of a thick
filament (composed of myosins) and a thin filament (composed of actin units) arranged
between two Z-discs and an M line running through the center. Troponins and
tropomyosines are arranged on the thin filament (31).
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Muscle contraction is initiated by an incoming action potential from the nerve endings,
transmitted via the acetylcholine receptors at the neuromuscular junction, which in turn
triggers the calcium release from the sarcoplasmic reticulum via the Ryanodyne
receptors (RyR) (5). The increase in cytosolic calcium concentration triggers calcium
binding to the Troponins, which changes their confirmation, providing a binding site for
the myosins. This leads to ATP hydrolysis by the myosins and a change in crossbridge
linking between actin and myosin, thus initiating muscle contraction (33). Sarcoplasmic
Reticulum Calcium ATPase (SERCA) pumps back the calcium in the sarcoplasmic
reticulum to cease the contraction.
The ability of skeletal muscle to generate force depends on the type of Myosin heavy
chain (MHC) present within the myofiber. Based on the MHC present, skeletal muscle
fibers can be classified into four fiber types: TypeI, Type IIa, Type IIb and Type IIx.
Differences between the fiber types are listed in Table 1.2. Type I fibers are the slow
twitch fibers, which are oxidative in nature owing to their high mitochondrial content.
They are important for endurance. Type II fibers are fast twitch fibers, IIa being
moderately fast and IIb and IIx being extremely fast, rely on anaerobic glycolysis for
energy, which makes them more prone to fatigue than Type I fibers (22). Interestingly, it
has been observed that obese individuals and type II diabetics have an increased
proportion of Type II fibers (29).
An important determinant of the skeletal muscle fiber types is PGC1α. PGC1α was
shown to be preferentially expressed in Type I fibers (34)and also shown to induce
mitochondrial biogenesis in skeletal muscle cells (35). Expression of PGC1α in Type II
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fibers in transgenic mice lead to their conversion to the mitochondria rich, type I fibers
(34) is the principal fiber type determinant.
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Table1.2: Fiber types in skeletal muscle
Type I

Type IIa

Type IIx

Type IIb

fibers

fibers

fibers

fibers

Fast

Fast

Fairly high

Moderate

Low

Long term

Short term

Short term

anaerobic

anaerobic

anaerobic

Hours

<30 mins

<5 mins

<1 min

Low

Medium

High

Very high

Very high

High

Medium

Low

High

High

Moderate

Low

Creatine

ATP, creatine

phosphate,

phosphate,

glycogen

glycogen

Moderateley
Contraction time

Resistance to

Slow
fast

High

fatigue

Activity used for

Maximum duration

Aerobic

of use
Power produced
Mitochondrial
density
Oxidative Capacity

Major Storage fuel

Triglycerides
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ATP creatine
phosphate

1.2.2: Thermogenesis in Skeletal Muscle
Skeletal muscle, apart from brown fat, is an important organ for thermogenesis. Three
types of thermogenesis occur in skeletal muscle- exercise induced thermogenesis, nonexercise induced thermogenesis and cold induced shivering thermogenesis (5).
Exercise induced thermogenesis is a well studied mechanism of decreasing body fat.
Non-exercise induced thermogenesis includes maintenance of general posture and
other activities of daily life. The most well known mechanism of defending the body
temperature in response to cold is shivering thermogenesis. Shivering is primarily a
function of skeletal muscle and is the body’s first response to cold. Shivering is known
to increase oxygen consumption by up to 5 times the basal metabolic rate (BMR) and
hence a very effective means of energy expenditure (36). A slight drop in core body
temperature activates the primary motor nerve center in the hypothalamus and triggers
the signal for skeletal muscle contraction. As the muscle contraction does not translate
into work, the energy is released as heat. During cold exposure (4-8oC), shivering
initially sets in, (it can take place for days during longer periods of cold exposure), until it
is replaced by non-shivering thermogenesis (NST), which is a primary function of brown
fat. NST is also beneficial because it prevents from any tissue damage to the skeletal
muscle because of excessive use. Recent studies have also shown that skeletal muscle
can contribute to NST (37). Skeletal muscle possesses sarcolipin, which uncouples
SERCA pump from the Ca2+ releasing Ryanodyne receptors and causes futile Ca2+
cycling, which leads to generation of heat. This effect was also observed in UCP1
deleted, brown fat ablated mice, suggesting that skeletal muscle is also capable of NST.
A potential mechanism for skeletal muscle NST could be through mitochondrial
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uncoupling, as occurs in BAT. Although skeletal muscle possesses UCP3, a homologue
of UCP1, its role in mitochondrial uncoupling is highly debated (38). No specific
uncoupling proteins like UCP1 have yet been identified in the skeletal muscle.
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Figure 1.4: Shivering thermogenesis in Muscle. Neurotransmitter-mediated opening
of cell-surface Na+ channels (1) leads to release of Ca2+into the cytoplasm from
sources both outside the cell (2) and the sarcoplasmic reticulum (3) via the ryanodine
receptor (RyR). Ca2+ release results in heat generation by ATP hydrolysis (4) during
both muscle relaxation and actin–myosin crossbridge cycling during sustained
contraction. Additional heat energy is released when Ca 2+ ions are pumped back into
the sarcoplasmic reticulum by the sarcoplasmic reticulum Ca2+ ATPases (SERCAs) (5)
(5).
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1.3: Brown fat and Skeletal Muscle- Two peas in a pod?
Given the common adipogenic features of both tissues, white fat and brown fat were
though to share a common developmental lineage. However, recent studies have
highlighted the fact that brown adipocytes carry a myogenic signature and are derived
from Myf5+ progenitors that give rise to the muscle cells (24). Although little was known
about the developmental origins of brown fat at this time, there were some studies that
suggested the finding that brown fat shares a developmental origin with skeletal muscle.
Hasty et al showed that myogenin mutant mice have defects in forming skeletal muscle,
but showed increased brown fat bundles in cervical and interscapular regions (39). This
finding was confirmed by Kablar et al almost 10 years after Hasty et al reported their
findings, that mice deficient in the myogenic transcription factors Myf5/Myod, have
defects in muscle formation, but they show an increased expression of adipose tissue in
place of muscle bundles (40). They however did not distinguish whether the excess
adipose tissue was white or brown. Lineage tracing experiments by Atit et al suggested
that some populations of brown fat, skeletal muscle and dermis all arise from Engrailed1
(En1) expressing population of the dermamyotome cells, which depends on the Wnt
signaling pathway (41). Microarray experiments from the Swedish group Cannon and
Nedergaard (42) again confirmed the myogenic signature of the brown fat. Another set
of independent studies identified PRDM16 as the ‘master regulator’ that controlled the
brown fat to skeletal muscle cell fate of the Myf5+ cells (24). Interestingly, when
PRDM16 was knocked out, the Myf5+ cells assumed a myogenic fate, suggesting that
PRDM16 plays an inhibitory role on differentiation of Myf5+ cells into skeletal muscle.
Given the common features of brown fat and skeletal muscle (abundance of
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mitochondria, regulation of energy expenditure and thermogenesis), these two tissues
make an attractive target for the treatment of obesity.
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Figure 1.5: Brown fat and skeletal muscle share a common developmental origin.
(11).

23

1.4: Mitochondria in obesity and metabolic syndrome
Mitochondria are important organelles in eukaryotes involved in the production of
chemical energy in form of ATP from oxidation of nutrients consumed. Mitochondria
have an inner and outer membrane, intermembrane space and a matrix. The inner
membrane is highly invaginated, forming numerous cristae. Breakdown of glucose by
glycolysis and tri-carboxylic acid cycle and oxidation of fatty acids generates substrates
(NADH and FADH2) that feed in to the electron transport chain (ETC) located in the
inner mitochondrial membrane (43). As mentioned in section 1.1.2, flow of electrons
across the ETC generates a proton gradient, which is harnessed by the ATP synthase
to generate ATP by phosphorylation of ADP.
Mitochondria play an important role in metabolic regulation and hence affect the whole
body energy homeostasis. Dysfunction of mitochondria can affect energy expenditure
and hence lead to the development of obesity (43). Studies on insulin resistant
individuals have highlighted the role of mitochondrial dysfunction- including decreased
number of mitochondria, decreased expression of the subunits of the electron transport
chain and also smaller mitochondria in skeletal muscle (30, 44). The mitochondria not
only show decreased respiration capacity, but also defective cristae formation and
overall structure. Interestingly expression of PGC1α, which is known to regulate
mitochondrial biogenesis, is downregulated in patients with Type II diabetes, suggesting
a co-relation between mitochondria number and development of insulin resistance (22).
Mitochondria are important for skeletal muscle function, which handles almost 80% of
insulin mediated glucose uptake and also for production of adequate amounts of ATP
required for skeletal muscle contraction. Dysregulation of mitochondrial function in
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skeletal muscle affects their ability to generate enough ATP, thereby decreasing the
necessary force production required for muscle contraction. This affects the overall
muscle function (43), leading to impaired substrate utilization (glucose and fatty acids),
which can lead to the development of obesity and metabolic syndrome (45).
Mitochondria also possess uncoupling proteins (UCP1, UCP2, UCP3) (46)in their inner
mitochondrial membranes. UCP1 is primarily present in brown fat whereas UCP2 shows
a more global distribution. UCP3 is present mainly in the skeletal muscle. So far, only
UCP1 is considered to be a true ‘uncoupling’ protein. UCP1 dissipates the ETC proton
gradient as heat, thereby increasing energy expenditure. Brown adipose tissue is also
extremely rich in mitochondria and any functional defects in mitochondria translate into
decreased energy expenditure and thermogenesis, which can ultimately result in
development of obesity (43).
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1.5: The JAK-STAT pathway
Discovered in the early 1990s while studying the actions of Interferon on cells, the JAKSTAT pathway is still being unraveled after twenty years. The JAKs (Janus kinases/
Just Another Kinases) and STATs (Signal Transducers and Activators of Transcription)
are a part of the signal transduction scheme acting downstream of the Interferon (IFN)
and cytokine receptors and are important for initial innate immune responses. The JAKSTAT pathway is also involved in regulating a multitude of cellular processes including
cell growth, differentiation and immune responses (47).
The cytokine receptors are comprised of a single transmembrane domain and an
extracellular domain that promotes ligand binding (48). Binding of a ligand causes
receptor homo or hetero dimerization or multimerization, depending on the ligand. The
receptors themselves lack any kinase activity, but receptor associated JAKs are brought
in close proximity and they auto and trans phosphorylate each other, leading to their
activation. Activated JAKs phosphorylate specific phosphotyrosine residues on the
receptor, which provides a binding site for the SH2 domain possessing STATs. The
STATs are also phosphorylated by JAKs, which releases them from the receptors,
allows them to dimerize, translocate to the nucleus and activate transcription of
respective genes (47, 49-51).
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Figure 1.6: The classical JAK-STAT pathway (Adapted from (50))
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1.5.1: JAK family of tyrosine kinases
Mammals have four JAKs- JAK1, JAK2, JAK3 and Tyk2 and seven STATs (STAT1-4,
STAT5A, 5B and 6). JAK1, JAK2 and Tyk2 are ubiquitously expressed, whereas JAK3
expression is restricted to the hematopoietic lineage (48, 50). JAKs are 120-140kd
proteins and share a common structure. The N-terminus of JAKs contains a Band 4.1
ezrin, radixin and moesin (FERM) domain (JH6-JH7) and an SH2-like domain (JH3JH4). The FERM domain of JAKs is implicated in mediating interaction with the cytokine
receptors. At the C-terminus, JAKs possess a kinase like (pseudokinase) domain (JH2)
and a kinase domain (JH1). The kinase like domain does not possess an ATP binding
catalytic site, however it is important for complete kinase activity of JAKs (48)The
phenotypes of JAK knockout mice are listed in Table 1.3. Apart from STATS, JAKs are
known to have other targets including SOCS proteins, IRS1/2, Grb2 and c-abl, (48).
JAKs are found on the plasma membrane, associated with their receptors; however
recent studies have provided a completely new perspective on JAK localization and
function. JAK2 has been shown to be present in the nucleus of numerous cell types
including hematopoietic cells, where it was shown to directly phosphorylate Y41 on
histone H3 (52). JAK1, along with JAK2 was also found to be constitutively present in
the nucleus of CHO cells (53). Interestingly, JAKs also affect transcription of genes
which are not STAT dependent. Tyk2 also shows constitutive localization in the nucleus
of human fibrosarcoma cells (54). Tyk2, along with the receptor complex, was also
shown to bind the promoters of IFN inducible genes following interferon treatment of
cells (55). The FERM domain contains an arginine rich region, which is thought to be
the putative nuclear localization sequence (NLS) for JAKs (54).
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Figure 1.7: Schematic structure of JAKs (Adapted from (50))
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Table 1.3: Phenotypes of JAK knockout mice (Adapted from (50)).
Cytokines whose signaling requires
Gene

Phenotype of mouse knockout
this Jak

Viable but early postnatal lethal

Families of receptor with the shared

owing to neurological deficits; SCID

subunits γc or gp130; IFNs

Jak1

IL-3; family of receptors with the shared
Embryonic lethal owing to a defect of
subunit gp130; IFN-γ hormone-like

Jak2
erythropoiesis

cytokines (EPO, GH, PRL, TPO)

Family of receptor with the shared
Jak3

SCID, viable and fertile
subunit γc

Viable and fertile; susceptible to
Tyk2

parasite infection; resistant to LPS;
resistant to collagen-induced arthritis
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IL-12; LPS

1.5.2: Tyk2 - structure, function and what we already know.
Tyk2 was the first of the JAKs to be discovered (56), and was found to play an important
role in IFNα/β signaling (57). Most of the early studies on Tyk2 were carried out in Tyk2
null human fibrosarcoma cells (58). Tyk2 requires the presence of both kinase like
domain and kinase domain for full catalytic activity (59). Point mutations in the kinase
like domain also lead to impaired kinase activity of Tyk2 (60). Tyk2 has two Tyrosines in
the kinase domain (Y1051/1052 in mice), phosphorylation of both is important for
complete ligand dependent activation of Tyk2, however mutation of the YYs does not
impair the kinase activity of Tyk2 (61). Interestingly, mutation of catalytic lysine K930 in
the ATP binding pocket of Tyk2 renders it kinase inactive, and is not phosphorylated
basally, however it is still capable of being phosphorylated upon IFN treatment (61).
While deletion of the N-terminus of Tyk2 has no direct effect on its catalytic activity, it is
indispensible for stabilizing interaction of Tyk2 with its receptors (62).
Tyk2 knockout mice were generated by three independent groups- Shimoda et al
replaced the first coding exon with a neo resistant gene cassette (63), Karshigoff et al
disrupted exons 3-9 (64) and Sheehan et al deleted the 5”UTR and the first coding ATG
(65). A naturally occurring mutant mouse of Tyk2 was also reported (66), containing a
single point mutation in the pseudokinase domain. Tyk2 knockout mice are viable and
fertile. Interestingly, as opposed to what was observed in the in-vitro model, Tyk2
knockout mice were found to be dispensable for their role in IFNα/β signaling (63, 64).
Tyk2 however plays an important role in protection from bacterial, protozoan and viral
infections by activating IL12 mediated IFNγ production in NK and T cells (67). Tyk2 also
plays an important role in allergic inflammations by regulating the downregulation of Th2
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mediated antibody production and recruitment of eosinophils in the airways (68).
Interestingly, Tyk2 knockout mice are Th2 skewed and also show increased IgE
production (68). Tyk2 deficient pro-B cells were shown to have a decreased
mitochondrial respiration capacity (69). Recent studies from our lab have highlighted a
novel role of Tyk2 in obesity. It was found that Tyk2 deficient mice become obese with
age (70) and develop the classical hallmarks of metabolic syndrome (Insulin resistance,
glucose intolerance). These mice do not have an increased energy intake, however they
clearly have a deficiency in energy expenditure. Brown fat, a key thermogenic tissue,
was developmentally and functionally defective in Tyk2 knockout mice. These mice also
cannot survive in the cold past 12 hours, whereas a wild type a mouse can survive in
cold i.e 4oC for up to weeks/months. This suggests that in the absence of Tyk2, there is
both, an impaired shivering response mediated by skeletal muscle and non-shivering
thermogenesis mainly mediated by the brown fat. Interestingly, Tyk2 knockout mice also
show exercise intolerance (69) when exercised on a treadmill, suggesting that they may
have defects in their skeletal muscle function.
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Figure 1.8: Tyk2 and its various activator cytokines (71). Tyk2 is usually found in
combination with other JAKs (JAk1 and JAK2) at the cytokine (IL and IFN) receptors.
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Two cases of Tyk2 deficiency in humans have been reported to date (72, 73).
Minegashi et al reported a 22 year old Japanese patient that displayed a Hyper-IgE like
syndrome. Similarly, Kilic et al reported an 8 year old Turkish patient that exhibited a
trend for elevated serum IgE levels, but not as significantly elevated as the Japanese
patient. Interestingly, both patients were susceptible to bacterial and viral infections.
Diagnosis of Tyk2 deficiency reported in the Turkish patient is fairly recent and hence
limited observations are reported till date, including deafness and a mental condition.
Studies on Japanese patient are consistent with the observations reported in Tyk2 mice,
including restricted response to IFNα/β, increased proportion of Th2 cells and
decreased IFNAR1 expression.
Given the skewed physiology observed in Tyk2 deficient mice and also human subjects,
more detailed studies on Tyk2 will help consolidate the role it plays and its targets in the
various physiological functions, which will help develop novel strategies to overcome
those deficiencies.
The following studies presented in this thesis highlight the role of Tyk2 in the lineage
specific determination of brown fat and skeletal muscle and also in their function.
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Chapter II: Materials and Methods
2.1: Reagents and antibodies
All chemicals and reagents were purchased from Sigma-Aldrich or indicated otherwise.
Antibodies were purchased from Cell Signaling (mouse monoclonal Stat3), SigmaAldrich (mouse monoclonal alpha-tubulin), Abcam (rabbit polyclonal UCP1, rabbit
polyclonal PRDM16, mouse monoclonal CEBPβ, rabbit polyclonal PGC1α). Rabbit Tyk2
antisera was a kind gift of Dr. Birgit Strobl (University of Veterinary Medicine, Vienna,
Austria). Mouse monoclonal antibodies, MHC2b (antibody developed by Stefano
Schiaffino), myogenin (antibody developed Woodring Wright) and MyHC (antibody
developed by Helen Blau) were obtained from the Developmental Studies Hybridoma
Bank, developed under the auspices of the NICHD and maintained by University of
Iowa, Department of Biology, Iowa City, IA-52242. MHC2a (goat polyclonal antibody)
was a kind gift from Dr. Zhen Yan (University of Virginia, Charlottesville, VA).
2.2: Animals
All the mice were bred and maintained in the MCV/VCU animal facility according to
Institutional Animal Care and Use Committee (IACUC) regulations. Male mice were
used for these studies. Tyk2 deficient mice (C57BL/6) were kindly provided by Dr. Ana
Gamero (Temple University School of Medicine, Philadelphia, USA). Mice carrying a
transgene encoding the Wild Type (WT) or Kinase Dead (KD) form of Tyk2, including an
upstream loxP- flanked stop sequence in the ubiquitously expressed Rosa26 locus were
generated. These mice were crossed 5 generations to Tyk2-/- mice (on C57Bl6/J
background) to eliminate interference from endogenous Tyk2 in the studies. Control
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animals were obtained by crossing WT and KD transgenics with a wild type (Tyk2+/+)
mouse (on C57Bl6/J background) for 5 generations. Mice (transgenic WT and KD on
Tyk2-/- and Tyk2+/+ background) expressing the WT or KD form of Tyk2 in BAT (brown
adipose tissue) and SKM (skeletal muscle) were obtained by crossing WT or KD
transgenic animals with mice expressing the Cre recombinase under control of the Myf5
promoter, allowing Myf5 lineage-specific expression of Cre

(24). SKM and Heart

specific expression of WT or KD form of Tyk2 was obtained by crossing the transgenic
mice with mice expressing Cre recombinase under control of MCK promotor (Muscle
Creatine Kinase) (74). Animals from the same mixed background strain generation were
compared. Mice were genotyped to confirm the expression of the transgene and the
specific cre recombinase.
2.3: Genotypings
Mice were genotyped using a modified HotSHOT genomic DNA isolation protocol.
Briefly, a tail snip was taken and incubated in 75μL of alkaline buffer (25mM NaOH,
0.2mM EDTA,pH 12.0) for 30minutes at 95°C. Samples were then cooled on ice and
then 75L of neutralization buffer (40mM Tris-HCl, pH2.0) was added. Samples were
vortexed and then centrifuged at 16,000xg for 5 minutes at room temperature. Then
100L of the reaction (approximately 100ng/L) was removed and stored at -20°C until
used for genotyping. To determine the genotype of the mice, the following PCR
reactions were set up. For Rosa, 2L DNA, 0.3l of 10M Rosa1, 0.3l of 10M Rosa2,
0.3l of 10M EGFP1 and 0.3l of 10M EGFP2 Primers,12.5L 2x GoTaq Hot Start
Green Master Mix (Promega, Madison, WI) and 5.3 L dH2O were added to a PCR
tube. The following PCR cycles were used 1) 95°C for 4minutes, 2) 95°C for 30
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seconds, 60°C for 30 seconds, 72°C for 45 seconds repeated 35 cycles 3) 72°C for 7
minutes. Myf5 cre PCR was set as follows- 2L DNA, 1.5l of 10M Myf5F, 1.5l of
10M Myf5R, 1.5l of 10M Myf5 mutant Primers,12.5L 2x GoTaq Hot Start Green
Master Mix (Promega, Madison, WI) and 6 L dH2O. For Tyk2 genotyping, PCR was
set as follows- 2L DNA, 1.0l of 10M Tyk2F, 1.0l of 10M Tyk2R, 1.0l of 10M
Primers,12.5L 2x GoTaq Hot Start Green Master Mix (Promega, Madison, WI) and
8.5L dH2O. For Neo genotyping, PCR was set as follows- 2L DNA, 1.0l of 10M
Tyk2F, 1.0l of 10M Neo8, 1.0l of Neo9 10M Primers,12.5L 2x GoTaq Hot Start
Green Master Mix (Promega, Madison, WI) and 8.5L dH2O. The following PCR cycles
were used for Myf5, Tyk2 and Neo: 1) 95°C for 3minutes, 2) 95°C for 30 seconds, 55°C
for 30 seconds, 72°C for 30 seconds repeated 35 cycles 3) 73°C for 5 minutes. For
MCK cre genotyping, PCR was set as follows- 2L DNA, 1.0l of 10M MCK F, 1.0l of
10M MCK R, 1.0l of 10M Primers,12.5L 2x GoTaq Hot Start Green Master Mix
(Promega, Madison, WI) and 8.5L dH2O. The following PCR cycles were used 1) 95°C
for 3 minutes, 2) 95°C for 30 seconds, 50°C for 30 seconds, 72°C for 45 seconds
repeated 35 cycles 3) 72°C for 10 minutes. The PCR products were resolved on a 1%
agarose/TBE gel with EtBr (ethidium bromide) to visualize the bands. Sequences of
primers used for genotypings are listed in Table 2.1.
2.4: Cell Culture
Brown fat preadipocytes were isolated as previously described (75, 76). Interscapular
brown adipose tissue was isolated from newborn Tyk2+/+, Tyk2-/-, Tyk2-/-+WT, Tyk2-/+KD mice, minced and subjected to collagenase A digestion (1.5 mg/ml in isolation
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buffer containing 123 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 5 mM glucose, 100 mM
HEPES and 4% BSA) for 40 min at 37oC. The digested tissue was filtered through a
70μM filter. Collected cells were centrifuged at 1500 rpm at room temperature for 5 min
and then resuspended in 1 ml of primary culture medium (Dulbecco’s modified Eagle
medium, 4500 mg/L glucose Gibco, Carlsbad, CA) containing 20% FBS, 20 mM HEPES
and 1% penicillin-streptomycin), transferred into 12 well plates and grown in a
humidified atmosphere of 5% CO2 and 95% O2 at 37°C. After 3 days of culture, cells
were immortalized by infection with puromycin resistance retroviral vector pBabe
encoding SV40 Large T antigen. 24 hrs after infection cells were split into 10 cm dishes
and maintained in primary culture media for the next 24 hrs and then subjected to
selection with puromycin at a concentration of 2 μg/ml in DMEM with 20% FBS for one
week.
For differentiation, brown preadipocytes were grown to 100% confluence in the
differentiation medium: DMEM containing 4500 mg/L glucose, 10% FBS, 20 nM insulin
and 1 nM triiodothyronine. Fully confluent cells were incubated for 48 h in differentiation
medium supplemented with Induction medium- 0.5 mM isobutylmethylxanthine (IBMX),
0.5μM dexamethasone and 0.125 mM indomethacin. After 48 hrs of induction, cells
were maintained in differentiation medium for 5 days.
2.5: Constructs and viral transductions
293T cells, used as packaging cells, were grown in complete DMEM medium containing
10% FBS and 1% penicillin-streptomycin. Cells were transfected in 10 cm dishes using
Fugene reagent, 5μg plasmid and 5μg of helper vector. (Roche Diagnostics,
Indianapolis, IN) according to the manufacturer’s instructions. Media was changed 24
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hrs after transfection. The virus-containing medium was collected 48 hrs after
transfection, centrifuged for 10 min at 500 x g and filtered through 0.45 μm filter. Viral
supernatants were added to the cells for 24 hrs in the presence of Polybrene (8 μg/ml
polybrene, Chemicon Int., Temecula,CA), then diluted twice with the fresh medium. The
next day the viral supernatant was removed and replaced by fresh medium.
2.6: Mitochondrial preparation
Skeletal muscle mitochondria were prepared as described previously (77) with a few
modifications. Briefly, muscles were minced finely with a blade, trimmed clean of visible
fat and connective tissue, and placed in 4 ml of modified Chappell-Perry (CP) buffer
(buffer CP1: 100 mM KCl, 50 mM 3-(N-morpholino) propanesulfonic acid (MOPS), 1
mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 5 mM
MgSO47H2O) supplemented with trypsin (8 mg per 2g of wet tissue). After 20 min
incubation at 4°C on a rotator, the digestion was stopped by adding an equal volume of
CP2 (CP1 supplemented with 5% defatted BSA). The tissue was homogenized using a
motor-driven Teflon-glass Potter homogenizer (3x). The supernatant was transferred to
a 50ml falcon tube and centrifuged at 1000 ×g for 5 min at 4°C. Mitochondria containing
supernatant was transferred to fresh eppendorfs and spun at 7800xg for 10 mins at 4°C.
Mito pellet was washed 3x with CP1 buffer. The final mitochondrial pellet after 3 washes
was resuspended in CP1 buffer and protein concentration was measured using the
Lowry method.
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2.7: Blue Native-PAGE
Electrophoresis of mitochondrial proteins in native conditions was performed using
NativePAGE Novex Bis-Tris Gel System (Invitrogen, Carlsbad,CA), according to the
manufacturer’s instructions with modifications. All chemicals purchased from Invitrogen
or stated otherwise. Briefly, mitochondria were solubilized in cold 1x NativePAGE
Sample Buffer containing DDM (n-dodecyl-β-D-maltoside) in the ratio of 1.6 g of
detergent per 1 g mitochondrial protein or containing digitonin in the ratio of 6 g of
detergent per 1 g protein. After 15 min of incubation on ice, the samples were
centrifuged at 16,000 x g for 30 min at 4oC and supernatants transferred to the new
tubes. The protein concentration of the lysates was determined using Bio-Rad protein
assay. Prior to the electrophoresis, 30 μg of the extract was combined with Coomassie
blue G-250 dye (detergent/dye ratio of 8 g per 1 g). Blue Native-PAGE was run using 4
– 16% gradient Novex NativePAGE Bis-Tris gels and NativePAGE Running Buffer. The
conditions of a run were as follows: low temperature (4oC) run, 150 V constant for 60
min, then the voltage was increased to 250 V constant for the remainder of the run
(about 60 min), upper (inner) chamber contained dark blue cathode buffer (NativePAGE
running buffer mixed with 0.02% Coomassie blue G-250 dye) which was exchanged
after the dye front reached 1/3rd of the gel into the light blue cathode buffer (0.002% G250). After the run gels were subjected to Coomassie staining. For Coomassie protein
staining, the native gels were first placed in 100 ml of Fix solution (40 % methanol, 10 %
acetic acid) and microwaved on high 60 (950 – 1100 watts) for 45 seconds followed by
30 min of incubation on an orbital shaker at RT. This procedure was repeated once and
gels were immersed in EZBlue Coomassie Brilliant Blue G-250 colloidal protein stain
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(Sigma-Aldrich, Saint Louis, MO) and left on orbital shaker for overnight at RT. Next
day, staining solution was decanted and gels were de-stained using ultrapure water until
the desired background was obtained, and they were then scanned.
2.8: In Gel complex assays
Following BN-PAGE on mitochondria samples solubilized in 10% DDM, the gel was
stained as follows for determining the activity of individual ETC complexes.
Complex I: Gel was incubated with 2mM Tris-HCl, pH 7.4, 0.1mg/mlNADH and
2.5mg/ml nitroblue tetrazolium at RT for 20 mins.
Complex II: Gel was incubated with 4.5mM EDTA, 10mM KCN, 0.2mM phenazine
methosulfate, 84mM succinic acid and 50mM nitroblue tetrazolium in 1.5mM phosphate
buffer, pH 7.4 at RT for 3 hrs.
Complex IV: Gel was incubated in 5mg diaminobenzidine dissolved in 9ml of 50mM
sodium phosphate, pH 7.2, 1ml catalase (20mg/ml), 10mg cytochrome c and 750mg
sucrose at RT for 3 hrs.
The color development for bands was preserved by fixing the gels in 50% methanol with
10% acetic acid for 15 mins. The fixed gels were stored in 10% acetic acid. The
resulting bands were quantified by densitometry with the help of Image-J software.
2.9: Oxygen Consumption assay
Polarographic measurement of oxygen consumption by intact mitochondria was
performed in a glass chamber equipped with Clark-type oxygen electrode (Strathkelvin
Instruments, Glasgow, Scotland) as previously described (75). The measurements were
done at 30oC in 500 μl of a respiration buffer (80 mM KCl, 50 mM MOPS, 1 mM EGTA,
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5 mM KH2PO4 and 1 mg/ml defatted BSA, at pH 7.4). For glutamate/malate-dependent
respiration (complex I) 300 μg of mitochondrial protein was used. For succinatedependent respiration (complex II), 200 μg of mitochondrial protein was used, and for
TMPD (N,N,N′,N′-tetramethyl-p-phenylenediamine)/ascorbate (complex IV), 100 μg of
protein was used. Next, the selected substrates for complex I (20 mM glutamate+5 mM
malate), complex II (20 mM succinate with 7.5 μM rotenone), or complex IV (1 mM
TMPD/20 mM L- ascorbate with 7.5 μM rotenone) of the respiratory chain were added
to the chamber. State 3 respiration was initiated by the addition of 0.2 mM ADP (final
concentration) followed by state 4 respiration. After state 4 was attained, 2 mM ADP
was added to the chambers to measure maximum rate of state 3 respiration. Finally,
0.04 mM uncoupler DNP (2,4-dinitrophenol) was used to measure the uncoupled
respiration rate. In case of TMPD/ascorbate, only maximum rate of state 3 (2 mM ADP)
was measurable. At the end of that measurement, 2 mM azide was added to determine
the specificity of complex IV-dependent oxygen consumption.
ADP-stimulated (state 3) and ADP-limited (state 4) respirations were defined and
calculated according to the method of Chance and Williams (75).
2.10: Histology
Skeletal muscle was fixed in 10% formalin and were paraffin-embedded. Multiple
sections were prepared and stained with hematoxylin and eosin (H&E) at the Pathology
Research Service Facility (VCU Medical Center, Richmond, VA).
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2.11: Electron microscopy
Skeletal muscle was fixed in 2% paraformaldehyde- 2% glutaraldehyde in 0.1 M
cacodylate buffer. The tissue samples were processed and analyzed at the Microscopy
Core Facility at the Department of Anatomy and Neurobiology (VCU Medical Center,
Richmond, VA).
2.12: Oil red O staining
The Oil red O staining was used to test for lipid accumulation in fully differentiated cells.
Plates with cells were rinsed once with PBS and then fixed with buffered formalin for 1
hr at room temperature. Fresh Oil red O working solution was prepared by adding 6 ml
of the stock solution (0.5 g Oil red O in 100 ml of 2-propanol) to 4 ml of dH2O, mixed
and filtered through Whatman filter paper. Following fixation the cells were incubated for
1hr at room temperature with Oil red O stain. Then plates were carefully rinsed several
times with dH2O and air-dried before collecting images under the inverted microscope.
2.13: RNA extraction and real-time qPCR
Total RNA was isolated with TRI Reagent (Molecular Research, Cincinnati, OH),
according to the manufacturer’s instructions. Briefly tissues were harvested and minced
finely and resuspended in 1ml TRI-reagent. Samples were incubated for 30 mins on a
rotator-shaker at 4°C.Then 250L cholorform was added to the Tri Reagent and the
samples were vortexed for 30 seconds and spun down at 13,200 rpm for 10 minutes at
4°C. The aqueous phase was taken and 500L of isopropanol was added. Samples
were vortexed and then incubated at -20oC for 30 minutes. RNA was pelleted at 13,200
rpm for 15 minutes at 4°C. The supernatant was removed and the RNA pellet was
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washed with 75% ethanol. The samples were then centrifuged at 13,200 rpm for 10
minutes at 4°C. Supernatant was removed and RNA pellet was dried at 37°C. RNA was
then re-suspended in the appropriate amount of DEPC H2O depending pellet size and
then incubated at 55°C for 10 minutes. Isolated RNAs were treated with DNase
(Promega, Madison, WI) in a 1:10 ratio with DNase and Buffer and incubated at 37°C
for 30 minutes. The treatment was stopped by using Stop Buffer (Promega, Madison,
WI) in a 1:10 ratio and incubated at 65°C for 10 minutes. RNA concentration was
measured using a nanodrop. cDNA was synthesized from 2 μg of RNA with the Tetro
cDNA Synthesis Kit (Bioline, Taunton, MA). 2g RNA, 1L Random Hexamer Primer
Mix, 1L 10mM dNTPs mix were preheated at 95°C for 1 minute then cooled to 4°C.
Then the 5x RT Buffer, 200U Reverse Transcriptase, 10U RNase Inhibitors, and DEPC
H2O was added to a final volume of 20L. The PCR was set as follows: 42°C for 50
minutes, 70°C for 15 minutes and then cooled to 4°C.
Real-time qPCR was performed using SensiMix SYBR and Fluorescein Kit (Bioline,
Taunton, MA) according to manufacturer’s instruction. . Briefly, the cDNA was diluted to
1:20 ratio and then 5L of the cDNA was used as the template for the reaction. The
reaction mixtures for internal controls were prepared as followed: 12.5L of SYBER
Green mix, 1L 5M forward primer, 1L 5M reverse primer, and 5.5L of dH2O. For
any other gene the mixture reaction is as followed: 12.5L of SYBER Green, 2.5L 5M
forward primer, 2.5L 5M reverse primer, and 2.5L dH2O. All the samples were
assayed in duplicates and analyzed using a CFX96 Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). Table 2.2 contains a full list of the primer sequences. Primers
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for Jak1 and Jak2 were purchased from SuperArray (Qiagen SABioscience, Frederick,
MD).
2.14: Protein Extraction
Cells were lysed in ice-cold extraction buffer (20 mM HEPES, 300 mM NaCl, 10 mM
KCl, 1 mM MgCl2, 20% glycerol, 1% Triton X-100) with added protease (COMPLETERoche) and phosphatase inhibitor cocktails (Roche, Indianapolis, IN) for 30 min at 4°C.
For isolation of protein from tissues, tissues were harvested and minced finely with a
blade and incubated with ice-cold extraction buffer for 30 mins on a rotator-shaker. After
lysis, cell debris was removed from the lysates by centrifugation at 13,000 x g for 10 min
at 4°C. The protein concentration in the supernatants was determined using a Bio-Rad
protein assay (Bio-Rad, Hercules, CA).
2.15: Western blot analysis
Equal amounts of protein were mixed 1:1 with 2X Laemmli sample buffer containing 1
mM β-mercaptoethanol. Samples were incubated at 95°C for 5 mins and separated
using SDS-PAGE electrophoresis (Running buffer: 25 mM Tris, 192 mM glycine,
0.1%SDS). The proteins were transferred to Immobilon-P polyvinyldifluoridine
membrane (activated by methanol) and soaked in transfer buffer (70% methanol, TrisHcl) (Millipore, Billerica, MA) using a semi-dry transfer apparatus (Bio-Rad, Hercules,
CA). Membranes were blocked for 1 h at room temperature with 5% non fat dry milk in
TBS-T buffer (20nM Tris-HCl, pH 7.5, 500mM NaCl, and 0.05% Tween-20) and then
incubated overnight at 4oC with the indicated primary antibodies in 5%BSA in TBS-T.
The blots were washed 3x in TBS-T. Secondary antibody was added (5% non fat dry
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milk in TBS-T buffer) for 1h at room temp. Samples were washed 3x in TBS-T and then
developed using ECL-Plus (Pierce Thermo Scientific, Rockford, IL).
2.16: Immunoprecipitation
250μg whole cell extracts were diluted with in an IP buffer pH 7.4 (150 mM NaCl, 50mM
Tris-HCl, 1% Triton, 1 mM EDTA with added protease and phosphatase inhibitor
cocktails (Roche, Indianapolis, IN) at 0.5μg/μl concentration. Samples were incubated
overnight at 4°C with Tyk2 antibodies (1:100 dilution) and 20μl agarose beads or control
IgG and agarose beads. Immunoprecipitates were washed five times with 1xPBS with
protease and phosphatase inhibitor cocktails. Beads were resuspended in laemlli buffer
with 1 mM β-mercaptoethanol. Samples were incubated at 95°C for 5 mins and beads
were pelleted. The supernatant was separated by SDS-PAGE and blotted with indicated
antibodies.
2.17: Chromatin Immunoprecipation (ChIP) assay
Tissues were isolated from mice, minced finely and resuspended in 20ml media
supplemented with 750μl formaldehyde for crosslinking. The samples were incubated
on a shaker 37°C for 20 minutes. To stop crosslinking, 125mM glycine was added and
samples were incubated on a shaker at RT for another 10 mins. The samples were then
spun down at 4°C, 450xg for 10 minutes. The supernatant was removed and pellet was
resuspended in 5ml PBS (supplemented with protease inhibitors). The samples were
then homogenised using a glass homogenizer till the homogenate was clear. This
homogenate was filtered using a 70μM cel strainer to get a single cell suspension.
Homogenate was aliquoted into eppendorf tubes and frozen at -80°C. Samples were
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then thawed and spun at 4°C , 7000rpm for 5 minutes. The pellet was resuspended in
1ml of lysis buffer (1%SDS, 10mM EDTA pH8.0, 50mM Tris-HCl, pH 8.0) and sonicated
10x 10 sec on-20 sec off cycle. The samples were then spun 4°C, 7000rpm for 10
minutes. Supernatant (chromatin) was pre-cleared as follows: 100μl supertanant+1ml IP
buffer (0.01%SDS, 1.1% Triton X, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.0, 16.7mM
NaCl) with inhibitors + 10μl ChIP beads (3x washed protein G sepharose beads
resuspended in equal volume of ChIP buffer with 10μl 1mg/ml BSA/ 100μl beads and
5μl 10mg.ml red herring DNA/100μl beads) on rotator at 4°C for 30 minutes. Beads
were pelleted to give a pre-cleared chromatin. 200μl was saved as input. IP was set as
follows: 1ml pre-cleared chromatin + 5μl antibodies on rotator at 4°C overnight. The
next day, 50μl ChIP beads were added and samples were incubated on a rotator at 4°C
for 2hrs. Beads were spun down at 6000 rpm at 4°C for 1 min and were washed 2x
(10mins rocking at 4°C followed by a spin at 6000 rpm for 1 min) with each of the
following buffers: ChIP buffer I (0.1%SDS, 1% Triton X, 2mM EDTA, 20mM Tris-HCl, pH
8.0, 150mM Nacl), ChIP buffer II (0.1%SDS, 1% Triton X, 2mM EDTA, 20mM Tris-HCl,
pH 8.0, 500mM Nacl), ChIP buffer III (0.25M LiCl, 1% NP.-40, 1% Sodium
Deoxycholate, 1mM EDTA, 20mM Tris-HCl, pH 8.0) and ChIP buffer IV (10mM TrisHCl, pH 8.0, 1mM EDTA). DNA was then eluted from the beads by adding 200μL ChIP
elution buffer (1%SDS, 0.1M NaHCO3) and rocking for 15 mins at RT. The beads were
pelleted at 6000 rpm. The supernatant (and also input sample that was saved
previously) was reverse cross-linked by adding 8μl 5M NaCl followed by o/n incubation
at 65°C. 1ml PB was addded and samples were purified on miniprep colums. Final DNA
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was eluted with 50μl buffer EB. This DNA was then used to set up qPCR for respective
promoters.
For setting up ChIP from cells, 1% formaldehyde was added to the media for 10mins to
fix cells. The cells were then washed with ice-cold PBS supplemented with 125mM
Glycine and protease inhibitors. The cells were scraped off in 1ml of PBS, transferred to
an eppendorf and pelleted at 6000 rpm, 4°C for 4 mins. The pellet was resuspended in
1ml ChIP lysis buffer and protocol was followed as described above.
2.18: Site-Directed Mutagenesis
Site-Directed mutagenesis was carried out according to manufactures instructions
(Strategene). Briefly, a PCR reaction was set as follows-5 µl of 10× reaction buffer, X µl
(50 ng) of dsDNA template, 1µl (125 ng) of oligonucleotide forward primer, 1 µl (125 ng)
of oligonucleotide reverse primer, 1 µl of dNTP mix , 1 µl pfu turbo, ddH2O to a final
volume of 50 µl. The PCR was set as follows: 1) 95°C for 30 sec 2) 95°C for 30
seconds, 55°C for 30 seconds, 68°C for 1min/kb of plasmid length, repeated 35 cycles
3) 72°C for 10 minutes. The PCR product was digested with Dpn1 at 37°C for 1 hr. 2 µl
of the digested product was then transformed into XL-gold ultracompetent cells (On ice
for 15 minutes, heat shock at 42°C for 50 sec, ice for 2 mins. Add 950 µl SOC medium
and shake at 37°C for 1hr. 50 µl of transformed bacteria was plated onto an ampicillin
selection plate and incubate o/n at 37°C). The resulting colonies were screened for the
mutation.

48

2.19: Statistical analysis
Results are presented as the mean ± SE. Statistical comparison was performed using
two-tailed Student’s t-test. While interpreting the data results a p-value less than 0.05
was considered statistically significant and annotated by *.
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Table 2.1: List of Primers for Genotyping
Primer

Sequence

Myf5 F

CGT AGA CGC CTG AAG AAG GTC AAC CA

Myf5 R

CAC ATT AGA AAA CCT GCC AAC ACC

Myf5 mutant

ACG AAG TTA GGT CCC TCG AC

Rosa1 F
Rosa1 R
EGFP1 F
EGFP1 R
MCK F
MCK R
Tyk2 F
Tyk2 R
Neo8
Neo9

CAA CGC CCA CAC ACC AGG TTA G
GCA CGT TTC CGA CTT GAG TTG CC
GCA AGC TGA CCC TGA AGT TCA TC
TCG TCC ATG CCG AGA GTG ATC C
ATG TCC AAT TTA CTG ACC G
CGC CGC ATA ACC AGT GAA AC
TGG ACA AAA TGG AGT GAG TGT AAG
CTG GGT CAT GGC TGG AAA AGC CCA
GAT CGG CCA TTG AAC AAG ATG
CGC CAA GTC CTT CAG CAA TAT
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Table 2.2: List of Primers for qPCR
Primer

Sequence
F: CTG GGC TTA ACG GGT CCT C

UCP1
R: CTGGGCTAGGTAGTGCCAGTG
F: CAGCACGGTGAAGCCATTC
PRDM16
R: GCGTGCATCCGCTTGTG
F: TGC TCT TCT GTA TCG CCC AGT
Cidea
R: GCC GTG TTA AGG AAT CTG CTG
F: GCCAACTATGCTGGAGCTGATGCCCMHCI
R: GGTGCGTGGAGCGCAAGTTTGTCATAAG
F: GGCACAAACTGCTGAAGCAGAGGC
MHC2a
R: GGTGCTCCTGAGGTTGGTCATCAGC
F: GAGCTACTGGATGCCAGTGAGCGCMHC2b
R: CTGGACGATGTCTTCCATCTCTCC
F:GGCAGCAGCAGCTGCGGAAGCAGAGTCTGG
MHC2x
R: GAGTGCTCCTCAGATTGGTCATTAGC
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F: GGA TGG AAA GGC TAT TGC AC
titin
R: CCT CGG TGT CTT CAG CT
F: GCCATCCTCAGACCCTAGC
Ryr1
R: CACTGCAGGACCACTTCATC
F: ACTGGGGTCAGAACTTCGTG
Serca1
R: CCAGGGGGTGATGTGTTTCT
F: CTTTGATTCCCCCGAAGATT
TnnT1
R: CCTTTTTCCGCTGTTCAAAG
F: CGCTGAGAAGGAGCGGGAA
TnnT3
R: GCCAGGTAGCTGCTGTAGT
F: AGCCCTCTTCACCTGTCTCA
TnnI1
R: TTACGGGAGGCAGTGATCTT
F: GATCTCAGGATGGGAGATGAG
TnnI2
R:TCTTTCTCCAGCTCTGTGGC
F: CACCTTTGGGTGGTGGAGT
TnnC2
R: GCCTTGAACTCAGCGATCAT
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Chapter III: Results
3.1: Tyk2-/- mice have normal skeletal muscle morphology
Our previous studies have shown that Tyk2-/- mice have defects in brown adipose
tissue (BAT) formation (70). Since brown adipose tissue and skeletal muscle are
derived from the same lineage of Myf5+ve mesenchymal stem cells (24), we wanted to
investigate if SKM of Tyk2-/- mice have any structural defects. Gastrocnemius,
plantarius and soleus muscle from 12 week old mice were isolated, fixed, sectioned and
stained with Hematoxylin and Eosin. As seen in Figure 3.1, Tyk2-/- mice exhibit a
normal skeletal muscle fiber formation and structure. This suggests that Tyk2 is not
required for differentiation of skeletal muscle.
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Figure 3.1: Tyk2-/- mice have a normal skeletal muscle morphology: Hematoxylin
and Eosin staining of Gastrocnemius muscle of 12 week old Tyk2+/+ and Tyk2-/- mice.
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3.2: Skeletal muscle of Tyk2-/- mice is not hypertrophied
NMR studies on Tyk2-/- mice indicated that 3 month old Tyk2-/- mice have increased
lean mass as compared to Tyk2+/+ mice (Gornicka et al, unpublished). To determine
whether the increased muscle mass is due to increased muscle hypertrophy or
increased number of muscle fibers, we measured individual muscle fiber area using
image-J software. As seen in Figure 3.2A, Tyk2-/- mice do not show an increase in fiber
size nor do they have increased number of fibers in a muscle cross section. We also
weighed individual Gastrocnemius, plantaris and soleus muscle from Tyk2+/+ and Tyk2/- mice. As seen in Figure 3.2B, the gross weights of individual muscle types are not
significantly changed. This suggests that the increase in muscle mass is not due to
hypertrophied muscle, but an overall increase in the body muscle mass.
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B
A

Figure 3.2: Skeletal muscle of Tyk2-/- mice is hot hypertrophied. A) Quantification
of muscle fiber area of a muscle cross section from figure 3.1, using Image-J software
(n= 6). B) Weights of individual muscle types isolated from 12-14 week old Tyk2+/+ and
Tyk2-/- mice (n=6), **p<0.01. Data are expressed as mean ± SEM.
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3.3: Expression of muscle transcription factors is unaltered in SKM of Tyk2-/mice
Our previous studies indicate that BAT of Tyk2-/- mice show increased expression of
skeletal muscle specific genes (70), most likely due to an imbalance in commitment of
the Myf5+ progenitors towards skeletal muscle, mediated by PRDM 16 (24). Since
Tyk2-/- mice also have increased muscle mass, we investigated whether there is also
an imbalance in the expression level of muscle specific genes in the skeletal muscle of
Tyk2-/- mice. As seen in figure 3.3, expression levels of the muscle transcription factors
MyoD and myogenin, and the uncoupling protein, UCP3, are not changed in Tyk2-/mice. Interestingly, the levels of muscle creatine kinase (MCK) are downregulated in
Tyk2-/- mice. MCK is responsible for phosphorylation of creatine, which is one of the
major fuels utilized by SKM. This would suggest an imbalance in energy utilization
(78)in Tyk2-/- mice.
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Figure 3.3: Expression of muscle specific mRNAs in Tyk2-/- mice: q-RT PCR on
gastrocnemius muscle of 12-14 week old Tyk2-/- and Tyk2+/+ mice. (n=6-8 mice per
group), **p<0.01. Data are expressed as mean ± SEM.
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3.4: Tyk2-/- mice may exhibit contractile defects
Since muscle contraction is an important function of the skeletal muscle, we wanted to
determine if Tyk2-/- mice exhibit any contractile defects. We measured the expression
of different troponins, which are a part of the sarcomeric assembly and involved in
muscle contraction. qRT-PCR analysis on SKM of 12-14 week old mice showed that the
expression of troponins is downregulated in Tyk2-/- mice (Figure 3.4). This suggests
that Tyk2-/- may play a role in regulating contractility of the skeletal muscle.
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Figure 3.4: Tyk2-/- mice may exhibit contractile defects: Expression of troponins T1,
T3, I1 and I2 in GA muscle of 12-14 week old mice measured by qRT-PCR. (n=6-8 mice
per group). **p<0.01, ***p<0.0001. Data are expressed as mean ± SEM.
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3.5: Tyk2-/- mice may exhibit defects in calcium signaling
Since calcium release triggers muscle contraction, we wanted to determine if Tyk2-/mice show a defect in calcium release which could affect the muscle contraction. We
measured the expression of Ryanodyne and SERCA receptors which are responsible
for calcium release and calcium take-up after a stimulus. Figure 3.5 suggests that Tyk2/- mice may exhibit a defect in calcium mediated contraction and could affect the muscle
function and its thermogenic capacity.
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Figure 3.5: Tyk2-/- mice have decreased expression of mRNAs regulating calcium
release: Expression of SERCA and Ryanodyne receptors in GA muscle of 12-14 week
old mice measured by qRT-PCR. (n=6-8 mice per group). *p<0.05, **p<0.01. Data are
expressed as mean ± SEM.
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3.6: Tyk2-/- do not show defects in sarcomere assembly
Our previous studies have shown that Tyk2-/- mice may have a defect in shivering
thermogenesis which is a function of skeletal muscle contraction (70). We wanted to
determine if these contractile defects in SKM function were due to a disorganised
sarcomere assembly. We isolated gastrocnemius, plantarius and soleus muscle from
Tyk2+/+ and Tyk2-/- mice and subjected them to electron microscopy. The electron
micrographs (Figure 3.6) reveal an organised structure of the sarcomere assembly in
Tyk2-/- mice, suggesting that the defects in SKM function in Tyk2-/- mice is not due to a
defect in structural assembly of the skeletal muscle.
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Figure 3.6: Tyk2-/- mice exhibit a normal skeletal muscle structure: Electron
micrographs of GA muscle, in 12 week old mice, showing the sarcomere assembly. N =
4-6 mice per group.
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3.7: Tyk2-/- mice do not have defects in neuro-muscular junction assembly
The neuro-muscular junction (NMJ) is responsible for transmitting signals from the
incoming nerve to the skeletal muscle in response to various stimuli including cold
exposure, which is responsible for inducing muscle contraction. Since Tyk2-/- mice
exhibit defects in stimuli induced muscle contraction, we wanted to determine whether
the defect was due to improper transmission of the incoming signal or due to the
downstream effectors involved in muscle contraction. To determine this, we isolated
individual muscle types (gastrocnemius, soleus, plantaris, tibelis anterior, diaphragm)
and stained them with labelled α-bungarotoxin from snake venom, which binds
specifically to the Acetylcholine receptors at the NMJ. As seen in figure 3.7, both
Tyk2+/+ and Tyk2-/- exhibit a normal NMJ assembly (characterized by pretzel shaped
staining), suggesting that the defects in Tyk2-/- mice lie downstream of the NMJ.
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Figure 3.7: Tyk2-/- mice have a normal NMJ assembly: a-bungarotoxin staining of
acetyl choline receptors at the NMJ assembly in GA muscle of 12 week old Tyk2+/+ and
Tyk2-/- mice. N= 3 mice per group.
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3.8: Contractile defects in Tyk2-/- are SKM specific
Apart from skeletal muscle, heart is another contractile tissue with similar contractile
apparatus. As seen in Figure 3.8, expression of titin, one of the sarcomeric assembly
proteins is downregulated in SKM, but is unchanged in the heart. This suggests that the
defect lies specific to the contractile apparatus of skeletal muscle.
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Figure 3.8: Contractile defects in Tyk2-/- mice are skeletal muscle specific:
Expression of Titin in GA muscle and heart of 12-14 week old mice measured by qRTPCR. (n=6-8 mice per group). **p<0.01. Data are expressed as mean ± SEM.
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3.9: Tyk2-/- mice have increased glycolytic fibers
Fast-twitch fibers (glycolytic) contain low numbers of mitochondria and are responsible
for short term muscle activities. Slow-twitch fibers (oxidative) are rich in mitochondria
and are responsible for endurance functions. Our previous studies demonstrate that
Tyk2-/- mice are exercise intolerent (69) and show a relatively lower endurance
capacity. Since oxidative fibers and mitochondria play an important role in endurance
function, we wanted to determine whether Tyk2-/- mice show an increased proportion of
glycolytic fibers which could contribute to this phenotype. As seen in Figure 3.9, Tyk2-/mice show an increased expression of MHC2b (the glycolytic fiber specific myosin
heavy chain) and a decresed expression of MHC2a (the oxidative fiber specific myosin
heavy chain) in gastrocnemius (mixed muscle). However, the expression of total myosin
heavy chains or myogenin (marker of terminal muscle differentiation) are unchanged.
This suggests that the decreased endurance phenotype is contributed by the increased
proportion of fast-twitch fibers.
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Figure 3.9: Tyk2-/- mice have an increased proportion of glycolytic fibers: Protein
expression of MHCs for Type I (MHC2a), Type II (MHC2b) and total MHCs in whole cell
extract on GA muscle of 12-14 week old mice was analysed by western blot.
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3.10: PGC1α is downregulated in SKM of Tyk2-/- mice
PGC1α plays an important role in skeletal muscle function as it is the key factor that
determines the different fiber types (fast-twitch versus slow-twitch) and also is involved
in mitochondrial biogenesis. Since Tyk2-/- mice showed a decrease in the slow,
oxidative fibers, we wanted to determine if PGC1α was one of the contributing factors.
RNA was isolated from gastrocnemius muscle of 12 week old mice and PGC1α
expression was determined by qRT-PCR. As seen in Figure 3.10, Tyk2-/- mice exhibit
decreased PGC1α expression, and this downregulation is skeletal muscle specific,
suggesting that PGC1α is one of the contributing factors towards the Tyk2-/- phenotype.
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Figure 3.10:PGC1α is downregulated in Tyk2-/- mice: Expression of PGC1α in GA
muscle and heart of 12-14 week old mice measured by qRT-PCR. (n=6-8 mice per
group). *p<0.05. Data are expressed as mean ± SEM.
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3.11: Tyk2-/- mice exhibit altered mitochondria morphology in SKM
From the previous figure, we know that PGC1α expression is downregulated in SKM of
Tyk2-/- mice. Since PGC1α is also the master regulator of mitochondrial biogenesis, we
wanted to determine whether the mitochondria morphology and number was affected in
SKM of Tyk2-/- mice. Electron micrographs on gastrocnemius (glycolytic) (Figures
3.11C, 3.11D) and soleus (oxidative) (Figures 3.11A, 3.11B) muscles of 12 week old
mice reveal that the number of mitochondria is not changed, however the morphology is
grossly altered (Figures 3.11A, 3.11C). Mitochondria in Tyk2-/- mice appear smaller as
compared to Tyk2+/+ mice in both Type I (mitochondria-rich) and Type II (mitochondriapoor) fibers and also show deformed cristae formation. This suggests that Tyk2 may
play a role in regulating the mitochondrial structure.
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Figure 3.11:Mitochondria in Tyk2-/- mice are deformed: Representative Electron
micrographs of Soleus (A),(B) and plantaris (C),(D) muscle in 12 week old Tyk2+/+ and
Tyk2-/- mice.
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3.12: Tyk2-/- mice exhibit defects in mitochondrial respiration
Next, we wanted to determine whether the mitochondria exhibit a defect in function
along with the structural defects. We isolated mitochondria from skeletal muscle of 1214 week old Tyk2+/+ and Tyk2-/- mice and measured respiration on isolated
mitochondria using a Clark-type oxygen electrode. We measured electron flow through
Complex I, Complex II and Complex IV by adddition of specific substrates. As seen in
Figure 3.12, Tyk2-/- mice exhibit decreased Glutamate-Malate (complex I), succinate
(complex II) and TMPD-ascorbate (Complex IV) dependent respiration. This could be
due to a defect in activities of all ETC complexes or Complex IV which is the last one in
the chain. Figure 3.12, also shows that State 3 (ADP-dependent) and State 4 (ADPindependent) respiration are both lower in Tyk2-/- mice. DNP and azide uncoupled
respiration is also decreased, suggesting that the defects lie in electron flow through
ETC and not in ATP synthase (Complex V).
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Figure 3.12: Tyk2-/- mice exhibit a defect in mitochondrial respiration: Oxygen
consumption was measured from isolated mitochondria of 12-14 week old Tyk2+/+ and
Tyk2-/- mice using specific substrates (Glutamate-malate for Complex I, succinate for
complex II and TMPD-Ascorbate for complex IV) in a Clark-type oxygen electrode. State
3 (ADP dependent), State 4 (ADP-independent), and uncoupled (DNP for complex I and
II and azide for complex IV) values are represented in the figure. (n= 10-12 mice per
group) *p<0.05.
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3.13: Tyk2-/- mice exhibit defect in CIV activity
To identify which ETC complex contributed to decreased in oxygen consumption in
skeletal muscle mitochondria, we measured activities of the different ETC complexes
using an In-gel assay. Isolated mitochondria from skeletal muscle of 12-14 week old
mice were resolved on a Blue-Native gel to separate the individual complexes and
enzymatic activities were measured based on colorimetric analysis (79). Figure 3.13
suggests that the defect lies in activity of Complex IV, which could contribute to the
overall decreased mitochondrial respiration.
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Figure 3.13: Complex IV activity is decreased in Tyk2-/- mice: (A) Activities of
complex I, complex II and complex IV were measured on isolated mitochondria from 1214 week old Tyk2+/+ and Tyk2-/- mice using an In-gel assay afterBN-PAGE. (B)
Quantification of Complex IV activity from (A) using Image-J software. N=4-6 mice per
group, *p<0.05.
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3.14: Decreased ComplexIV activity in Tyk2-/- mice is not due to a defect in
assembly of the ETC
Decreased complex IV activity in the SKM mitochondria of Tyk2-/- mice could be due to
decreased expression of complex IV proteins or a defect in overall assembly of the ETC
complexes. Figure 3.14A shows that Tyk2-/- mice do not show any changes in the
expression or assembly of the different ETC complexes, nor the expression of
mitochondrial proteins (Figure 3.14B) is different between Tyk2+/+ and Tyk2-/- mice,
suggesting that the defect is activity of complex IV is not due to a structural defect in the
assembly of ETC components.
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Figure 3.14: Decreased ComplexIV activity in Tyk2-/- mice is not due to a defect in
assembly of the ETC: Mitochondria were isolated from 12-14 week old Tyk2+/+ and
Tyk2-/- mice and resolved on BN-PAGE. Mitochondria solobilised with DDM show ETC
complexes while mitochondria solubilised using digitonin show ETC supercomplex
formation. B) Western blot on isolated mitochondria from 12-14 week old Tyk2+/+ and
Tyk2-/- mice.
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3.15: Tyk2-/- mice exhibit SKM defects from birth
We wanted to determine whether the defects seen in SKM of Tyk2-/- mice are present
from birth or they develop with age. We isolated RNA from skeletal muscles from 1-3
day old newborn pups and measured the expression of troponins and MHCs by qRTPCR. As seen in Figure 3.15 A, expression of troponins is downregulated in Tyk2-/mice suggesting that the pups also exhibit contractile defects. Figure 3.16B shows that
expression of MHCI, the slow-oxidative type muscle fiber MHC is downregulated,
suggesting that Tyk2-/- mice exhibit a developmental defect in SKM function.
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Figure 3.15: Tyk2-/- mice exhibit SKM defects from birth: Expression of Troponins
(A) and Myosin Heavy Chains (B) in skeletal muscle 1-3 day old newborn pups
measured by qRT-PCR. (n=8-10 mice per group). *p<0.05. **p<0.01. Data are
expressed as mean ± SEM.
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3.16: Tyk2 is induced during differentiation of C2C12 myocytes
To determine if Tyk2 is involved during the differentiation of SKM, we used an in-vitro
approach. We measured the levels of Tyk2 RNA and protein during the differenetiation
of C2C12 myocytes. As seen in Figure 3.16A, Tyk2 is barely detectable in
undifferentiated, proliferating myocytes. However, Tyk2 levels increase (~20 fold) soon
after C2C12 myocytes are induced for differentiation and the upregulation is maintained
in differentiated myocytes. We also measured the expression of Jak1 and Jak2 (Figure
3.16B), which are known to be involved in myogenic differentiation. Jak1 is known to be
upregulated during the proliferation stage (80)and Jak2 is known to be involved in the
differentiation of C2C12 myocytes (81). This suggests that Tyk2 may be involved in
differentiation of myocytes and is indispensable for SKM function.
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Figure 3.16: Tyk2 is induced during differentiation of C2C12 myocytes: Western
blot analysis (A) and qPCR (B) on whole cell extracts of C2C12 myocytes during the
course of differentiation.
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3.17: Restoring expression of Tyk2 in BAT and SKM (Myf5 cre)
We next wanted to determine whether restroring the expression of Tyk2 in the Myf5
positive progenitors- BAT and SKM, will reverse the obese phenotype in Tyk2-/- mice.
Our preliminary results showed that restoring the expression of Tyk2 (Tyk2 WT) in
Tyk2-/- brown preadipocytes can differentiate into brown fat in-vitro (70). We also
expressed kinase inactive Tyk2 (Tyk2 KD) in Tyk2-/- preadipocytes as a control for
kinase activity. To our surprise, expression of Tyk2 KD also induced differentiation of
brown fat preadipocytes in vitro. To further investigate the role of kinase inactive Tyk2,
we generated mice carrying Tyk2 (Tyk2 WT) and kinase inactive Tyk2 (Tyk2 KD)
transgene. These mice were bred with Tyk2-/- mice on C57/Bl6 background. These
mice were then crossed to Myf5 cre mice (on Tyk2-/- background) to generate
transgenic mice that expressed either Tyk2 WT (Tyk2WTMyf5) or Tyk2 KD (Tyk2KDMyf5)
proteins. Tyk2-/- littermate control animals carried the inactive transgene.

Tyk2+/+

control animals were generated in a similar fashion, the only difference being that they
expressed endogenous Tyk2 and carried an inactive transgene. As seen in figure 3.17,
the transgene was expressed only in BAT and SKM, but not other tissues.
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Figure 3.17: Expressing Tyk2 in the Myf5 lineage: Whole cell extracts from BAT,
SKM, WAT and Heart from Tyk2+/+, Tyk2-/-, Tyk2-/-+Tyk2WT, Tyk2-/-+Tyk2KD mice
were analysed by western blot forTyk2 levels in 4 week old male mice. N= 3-4 mice per
group.

87

3.18: Tyk2 expression in BAT and SKM restores the obese phenotype
The first question that we wanted to address using the transgenic model was whether
mice expressing Tyk2WTMyf5 and Tyk2KDMyf5 revert their obese phenotype. Mice were
weighed every week for 6 months. The weights are plotted in Figure 3.18. Figure 3.18A
shows that the lean phenotype is restored in both Tyk2WTMyf5 and Tyk2KDMyf5 mice as
early as 12 weeks of age and is maintained till the mice are 6 months old (Figure
3.18B). This suggests that kinase activity of Tyk2 is not required for its role in regulating
the obese phenotype and that restoring expression of Tyk2 in BAT and SKM is sufficient
to revert the obese phenotype of Tyk2-/- mice.
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A

B

Figure 3.18: Tyk2 expression in BAT and SKM restores the obese phenotype:
Body weight of mice at 12 weeks (A) and 24 weeks (B) fed a breeder chow diet. (n= 1524 mice per group). ***p<0.0001. Data are expressed as mean ± SEM.
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3.19: Tyk2 expression in BAT (Myf5 cre) restores the brown fat phenotype in
primary preadipocytes
To determine whether brown fat development was restored in mice expressing
Tyk2WTMyf5 and Tyk2KDMyf5, we isolated preadipocytes from 1-3 day old newborn pups
and subjected them to in-vitro differentiation. As seen in Figure 3.19A, expression of
Tyk2WT and Tyk2KD restored the expression of brown fat specific genes (UCP1, cidea,
PRDM16) and fat specific genes (PPARα, PGC1α). Also, muscle specific genes (MCK,
MyoD) that were upregulated in Tyk2-/- mice were downregulated back to their normal
levels in both Tyk2WT and Tyk2KD preadipocytes (figure 3.19B). This suggests that
expression of Tyk2 in myf5 cre restores the brown fat phenotype in these mice.
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A

B

Figure 3.19: Expression of Tyk2 in BAT rescues the brown fat phenotype:
Expression of brown fat specific genes (UCP1, cidea, PRDM16) and fat specific genes
(PPARa, PGC1a) (A) and muscle specific genes (MCK, MyoD) (B) in differentiated
primary brow fat adipocytes measured by qRT-PCR. (n=3-5 mice per group). *p<0.05.
**p<0.01. Data are expressed as mean ± SEM.
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3.20: Restoring Tyk2 expression in BAT and SKM restores the thermogenic
function of these tissues
Since Tyk2-/- mice showed a defective response to cold exposure, we next determined
whether Tyk2WTMyf5 and Tyk2KDMyf5 transgenics restored their ability for cold tolerance.
12-14 week old mice were subjected to cold stress at 4oC for a period of 12 hours. Core
body temperature was monitored at regular intervals. Figure 3.21 shows that both
Tyk2WTMyf5 and Tyk2KDMyf5 can maintain the core body temperature as effectively as
the Tyk2+/+ mice. This shows that function of SKM and BAT is not dependent on kinase
activity of Tyk2.
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Figure 3.20: Tyk2 expression in BAT and SKM restores the thermogenic function
of these tissues: Core body temperature measured at 0.5, 1.5, 3, 6 and 12 hours using
a rectal thermometer in 12-14 week old mice placed at 4oC for 12 hours. (n=3-7 mice
per group) p<0.05. Data are expressed as mean ± SEM.
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3.21: Restoring Tyk2 expression in the SKM alone reverts the obese phenotype in
Tyk2-/- mice
Since SKM is an important tissue controlling energy expenditure, we wanted to
determine whether expressing Tyk2WT and Tyk2KD only in the SKM, but not BAT, of
Tyk2-/- mice is sufficient to revert the obese phenotype. We crossed the Tyk2WT and
Tyk2KD transgenic mice on Tyk2-/- background to mice carrying the cre recombinase
under the MCK (muscle creatine kinase) promoter. This allows expression of the
transgene in SKM and heart, but not BAT. The mice generated (along with Tyk2-/- and
Tyk2+/+ controls) were weighed every week for a period of 6 months. As seen in Figure
3.21A, at 12 weeks, Tyk2WTMCK and Tyk2KDMCK mice are significantly lighter than
Tyk2-/- mice, but are still heavy compared to Tyk2+/+ mice. Interestingly, at 24 weeks
(figure 3.21B), the Tyk2KDMCK mice show a complete reversal of obese phenotype,
whereas Tyk2WTMCK mice show a moderate reversal. The effects seen are SKM
specific, as the expression of genes involved in BAT function are downregulated, as in
Tyk2-/- mice (Figure 3.21C). This suggests that expressing Tyk2 in the SKM alone can
overcome the weight gain in Tyk2-/- mice and that kinase inactive form of Tyk2 is more
effective in reversal of obese phenotype in Tyk2-/- mice.
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Figure 3.21: Tyk2 expression in SKM alone partially reverts the obese phenotype
in Tyk2-/- mice: Body weight of mice at A) 12 weeks B) 24 weeks fed a breeder chow
diet. (n= 5-24 mice per group) C) Expression of BAT specific genes-UCP1, PRDM16
and cidea in BAT of 24 week old mice analysed by qPCR. ***p<0.0001, **p<0.01,
*p<0.05. Data are expressed as mean ± SEM.
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3.22: FERM domain of Tyk2 is required for the control of obesity
From the previous figures, we can conclude that kinase activity of Tyk2, as a function of
K927 in the JH1 domain, is dispensable for its role in regulating obesity, suggesting that
Tyk2 may act as an adaptor protein and not as a kinase. Reports suggest that the Nterm FERM domain is important for protein-protein interaction of Tyk2. To determine
whether the FERM domain is involved in mediating function of Tyk2 in obesity, we
generated FERM domain deletion of Tyk2. Brown fat preadipocytes from Tyk2-/- mice
were infected with these constructs and differentiated in- vitro. Oil-red O staining was
used as a marker for differentiation. As seen in figure 3.22, deletion of FERM domain in
both WT and KD forms of Tyk2, did not restore the differentiation of Tyk2-/preadipocytes. This suggests that the FERM domain of Tyk2 may be involved in
regulation of its function in obesity.
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Figure 3.22: FERM domain of Tyk2 is important for its role in regulating obesity:
Brown fat preadipocytes infected with the FERM domain deleted forms of Tyk2, sorted
by FACS to selects cells expressing the tyk2 constructs (GFP) .Oil red-O staining was
carried out after differentiation N = 3.
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3.23: Tyk2 interacts with transcription factors involved in BAT differentiation and
function
It has been well defined that the FERM domain of Tyk2 contains a nuclear-localization
sequence (NLS) (54) and that Tyk2 also binds to the promoter region of IFN inducible
genes along with its receptors IFNAR1 and IFNAR2 (55). We wanted to investigate
whether the function of Tyk2 in obesity is because of its nuclear interactions. We
immunoprecipitated Tyk2 from BAT of Tyk2WTMyf5 and Tyk2KDMyf5 mice and
determined its interaction with transcription factors involved in BAT differentiation
(PRDM16, C/EBPβ) and function (PGC1α,). As seen in Figure 3.25A, both Tyk2WT and
Tyk2KD interact with PRDM16, C/EBPβ and PGC1α, suggesting that Tyk2 may be a
part of the transcriptional complex regulating brown fat differentiation and function. We
also performed a chromatin immunoprecipitation assay (ChIP) in brown fat of Tyk2+/+
mice with Tyk2 antibody and determined Tyk2 binding at the promoter regions of brown
fat genes, UCP1 and PRDM16. As seen in Figure 3.23B, we did observe Tyk2 binding
at these promoters and this binding is highly specific (figure 3.23C), suggesting a role
for Tyk2 in regulating expression of genes involved in brown fat differentiation and
function.
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Figure 3.23: Tyk2 interacts with transcription factors involved in BAT
differentiation and function: A) Whole cell extracts of BAT from Tyk2WT Myf5 and
Tyk2KDMyf5 mice were immunoprecipitated with antibodies against Tyk2 and western
blotted for PGC1α, C/EBPβ and PRDM16. IgG was used as unspecific control. N = 3.
ChIP on BAT of 12 week old Tyk2+/+ mice. BAT from age matched Tyk2-/- mice were
used as an unspecific control. qPCR was carried out to check for Tyk2 binding at A)
UCP1 and PRDM16 promotor regions B) different regions upstream of UCP1 promoter
showing the specificity of Tyk2 binding. N = 3, ***p<0.001.
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3.24: Interaction of Tyk2 with PGC1α is induced under starvation in SKM
To further investigate whether the involvement of Tyk2 in skeletal muscle function is
also beacuse of its nuclear interactions, we immunoprecipitated Tyk2 from SKM of
Tyk2+/+ mice and determined its interaction with PGC1α which is important for skeletal
muscle function. As seen in Figure 3.24, Tyk2 interacts with PGC1α, under starvation,
when PGC1α levels are elevated (82). Interestingly, Tyk2 also interacts with the
transcription factor C/EBPβ, which is involved in adult myogenesis. This suggests that
Tyk2 may be a part of the transcriptional complex regulating skeletal muscle
differentiation and function.
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Figure 3.24: Tyk2 intercats with PGC1α in a starvation dependent fashion: Whole
cell extracts of SKM Tyk2+/+ mice were immunoprecipitated with antibodies against
Tyk2 and western blotted for PGC1α, C/EBPβ. IgG was used as unspecific control.
N=3.
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Chapter IV: Discussion
The work presented in this thesis highlights the role of Tyk2 in regulating the
development and function brown fat and skeletal muscle derived from the Myf5+
progenitors of the mesenchymal lineage. Our previous work characterized the functional
defects in brown fat of Tyk2 deficient mice (70).
Since we used a global knockout of Tyk2, the obese phenotype seen in the Tyk2
deficient mice could be a function of not only brown fat, but also other important
contributing factors including a defect in the regulation of energy balance mediated by
the hypothalamus (83), decreased energy expenditure as a function of skeletal muscle
(29, 44) and adipose tissue inflammation leading to insulin resistance (84). Skeletal
muscle, like brown fat, is a mitochondria rich tissue, is important in regulating energy
expenditure (38) and handles almost 80% of insulin mediated glucose uptake (30).
Since both brown fat and skeletal muscle share common embryonic origins, we wanted
to investigate the role of Tyk2 in skeletal muscle development and function.
Interestingly, Tyk2 along with Jak2 has been observed in regulation of lineage specific
determination of mouse embryonic stem cells (85). All JAKs are known to be expressed
in mouse embryonic stem cells (mESCs). Tyk2 is phosphorylated along with JAK1 and
JAK2 in mESCs following LIF treatment, suggesting their involvement in regulating
mESC cell renewal (86).
Body composition of Tyk2 deficient mice by NMR suggested that 3 month old knockout
mice have an increased proportion of lean mass as compared to fat mass (A. Gornicka,
unpublished data). Interestingly, brown adipose tissue also exhibited an increased
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proportion of muscle specific genes (70), suggesting a dysregulation of the Myf5+
descendants. The increased skeletal muscle mass could be a result of hypertrophied
muscle. Cross sections of Tyk2 deficient skeletal muscle ruled out muscle hypertrophy,
suggesting that there was an increase in overall number of skeletal muscle fibers in the
Tyk2 deficient animals. Interestingly, as observed in brown fat, Tyk2 deficient mice did
not exhibit an increased expression of skeletal muscle genes in the muscle. On the
contrary, levels of muscle creatine kinase, which also regulates the phosphorylation of
creatine, was downregulated in these mice. Phospho-creatine is a major source of fuel
for the muscles. This suggested an energy imbalance (78) and insufficient supply of fuel
to the muscles for contraction.
Tyk2 deficient mice also show decreased expression of troponins, which are involved in
regulating skeletal muscle contraction. This defect is observed even in newborn pups
suggesting that the defects in muscle contraction are developmental and do not just
accumulate with age. Previous studies by our group showed that Tyk2 deficient mice
are exercise intolerant (69). This defect could be a function of impaired skeletal muscle
contraction and/or dysfunctional mitochondria, which provide the necessary fuel for
muscle contraction. Electron micrographs on skeletal muscle show smaller mitochondria
with improper cristae formation in Tyk2 deficient mice. Interestingly, the number of
mitochondria as observed in the different fiber types (both mitochondria rich type I and
mitochondria poor Type II) was not much different between the wild type and Tyk2
deficient mice. These mitochondria are not only structurally defective, but they also
exhibit decreased oxygen consumption as a function of decreased activity of complex IV
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of the ETC. This suggests a role for Tyk2 in regulating the skeletal muscle contraction
and also mitochondria formation and function.
Interestingly, expression of PGC1α, which is an important regulator of mitochondrial
biogenesis, is also downregulated in Tyk2 deficient mice. PGC1α regulates the skeletal
muscle fiber type determination (22). Tyk2 deficient mice exhibit an increased
proportion of Type IIb (glycolytic) fibers, which have relatively low abundance of
mitochondria. This could account for the exercise intolerant phenotype observed in Tyk2
deficient mice.
Numerous reports suggest the involvement of JAK-STAT pathway in regulating
myogenesis (81, 87). JAK1 is required during initial myoblast proliferation stage
whereas JAK2 is activated during the differentiation phage. JAK1 along with STAT1 and
STAT3 also functions as a checkpoint to prevent myoblasts from premature
differentiation. Knockdown of JAK1 induces increased myogenic differentiation with a
concomitant reduction in cell proliferation (88). Interestingly, JAK2 along with STAT2
and STAT3 regulates the myoblast differentiation by activating the transcription factors
MyoD and MFE2, which are involved in myogenic differentiation (81). As opposed to
JAK1, knockdown of JAK2 inhibited myogenic differentiation, suggesting that JAK2 is
required for skeletal muscle differentiation. JAK3, which was known to be restricted to
the hematopoetic lineage, was also detected in proliferating myoblasts (89) and shown
to play an inhibitory role on proliferating myoblasts. Apart from its involvement in
myogenesis, JAK2 was found at the neuro-muscular junction along with ephrin receptor
4A (Epr4A) and shown to regulate the expression of acetylcholine esterase, the critical
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enzyme that hydrolyzed the neurotransmitter acetylcholine at the NMJ. This suggests a
functional role for JAKs in regulating muscle contraction.
We used an in-vitro system to determine whether Tyk2 plays a role in the development
of skeletal muscle. During differentiation of C2C12 myocytes, we observed that Tyk2
protein levels dramatically increase during the initial differentiation phase and stay
elevated throughout differentiation. This increase is specific to Tyk2 and not other JAKs.
This suggests that although Tyk2 levels are regulated during differentiation of skeletal
muscle, it is dispensable for structural development of skeletal muscle. However, is
required for the function of skeletal muscle.
The development of obesity in Tyk2 knockout mice was a result of global Tyk2
knockdown. Although expression of constitutively active Stat3 in the brown fat of Tyk2-/mice, using the fat-specific ap2 cre (expresses in brown fat, white fat or both, after birth)
reverted the obese phenotype (70), expression of Tyk2 transgene (Tyk2WT and
Tyk2KD) in brown fat alone using the ap2 cre, was not sufficient to revert the obese
phenotype (M. Derecka, unpublished data). This suggested that either Tyk2 has to be
expressed in tissues other than brown fat and/or the timing of Tyk2 expression is very
critical and needs to be expressed early in development. We addressed this issue of
temporal and spatial regulation of Tyk2 using two cre systems. Using Myf5 cre, we
expressed Tyk2 in both brown fat and skeletal muscle at E8.5 in the mouse embryo. We
also used MCK cre, which allowed the expression of Tyk2 in skeletal muscle and heart,
but not brown fat. Our earlier studies pointed that expressing a kinase inactive form of
Tyk2 in Tyk2-/- brown fat preadipocytes can restore their differentiation in vitro
(M.Derecka, unpublished data), suggesting that Tyk2 may not function as a kinase in
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brown fat development. To this end, we generated two transgenic mouse lines that
carried the wild type and kinase inactive allele of Tyk2. With both transgenes activated
under the Myf5 promoter, we observed a complete reversal of the obese phenotype.
This effect was observed as early as in 12 week old mice and the lean phenotype was
maintained even in 6 month old animals. Cold exposure studies confirmed activation of
thermogenesis in the transgenic mice, suggesting the functional rescue of both/either
brown fat and skeletal muscle. The in-vitro differentiation of brown fat preadipocytes
was also recovered in both the transgenic lines, confirming the novel role of kinase
inactive Tyk2 in brown fat differentiation and function.
Using the MCK cre transgenic mice, we wanted to delineate whether expression of Tyk2
in skeletal muscle was sufficient to revert the obese phenotype or it also required the
function of brown fat. 12 week old Tyk2WTMCK and Tyk2KDMCK mice are significantly
lighter than Tyk2-/- mice, but are still heavy compared to Tyk2+/+ mice. Interestingly, at
24 weeks, the Tyk2KDMCK mice completely revert the obese phenotype, whereas the
Tyk2WTMCK mice partially revert the obese phenotype. This suggests that the kinase
activity of Tyk2 is not required for its role in skeletal muscle function. Interestingly, these
results go along with our in-vitro brown preadipocyte differentiation model where we
observe that kinase dead Tyk2 is more effective in rescuing the differentiation in Tyk2-/preadipocytes. Why the kinase inactive Tyk2 appears to be more effective than the wildtype form of Tyk2 is still not clear. One reason could be that the kinase activity of Tyk2
may have an inhibitory role on its function. Since Tyk2 has been shown to have nuclear
actions, it may be possible that Tyk2 could phosphorylate the histones and inhibit
transcription of genes that regulate skeletal muscle function. Alternatively, the kinase
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inactive Tyk2 is more effective in interacting with proteins regulating muscle function.
More studies need to be carried out to address this issue. Unlike the reports suggesting
that kinase inactive form of Tyk2 is prone to proteasomal degradation (90), we did not
see any differences in the expression of Tyk2 levels in our Tyk2KD MCK and Tyk2KDMyf5
transgenic mice. Also, BAT development is not restored in these mice. This suggests
that Tyk2 expression is required for proper skeletal muscle function and/or kinase
activity of Tyk2 is inhibitory in skeletal muscle function. Co-expression of Tyk2 in brown
fat and skeletal muscle may be required for optimal regulation of energy expenditure.
Our results suggest that Tyk2 does not function as a classical JAK-STAT tyrosine
kinase, since the kinase dead form of Tyk2 works as effectively as wild type Tyk2 to
revert the obese phenotype in Tyk2 deficient mice. Non-classical functions of the JAK
kinases are not unheard of. Until recently, involvement of JAKs in gene expression was
thought to be restricted to their actions as receptor-associated tyrosine kinases,
activating the STAT transcription factors. Recent reports suggest the presence of JAKs
in the nucleus and also provide evidence that JAKs also can phosphorylate other target
molecules apart from STATs (91). JAK2 in the nucleus was shown to phosphorylate
Y41 on histone H3 and regulate genes involved in hematopoiesis and leukemia (52).
Reports also suggest a nuclear localization of Tyk2 (54) and its role in gene regulation
by binding to their promoters (55). On similar lines, we found an interaction of Tyk2 with
PRDM16, PGC1α and C/EBPβ, the transcriptional complex regulating brown fat
differentiation and function. In skeletal muscle, we found starvation-induced association
of Tyk2 with PGC1α. The FERM domain deletion mutant of Tyk2, which is known to
affect its nuclear localization, did not recover the differentiation capacity of Tyk2-/-
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brown fat preadipocytes. This suggests that nuclear actions of Tyk2 are required for its
role in regulation and differentiation of the thermogenic tissues. We speculate that Tyk2,
along with PRDM16, may be a part of the transcriptional machinery regulating the
brown fat differentiation.
Our studies suggest that Tyk2 is required at two different stages of development. First, it
may be required for the commitment of the Myf5+ progenitors towards developing
brown fat and plays an inhibitory role towards commitment of these progenitors towards
skeletal muscle (Figure 4.1). Secondly, Tyk2 may also be required for the function of
brown fat and skeletal muscle, by regulating the expression of genes involved in brown
fat and skeletal muscle differentiation and/or function (Figure 4.2). It is also interesting
to note that levels of Tyk2 in the skeletal muscle are much lower compared to other
tissues in a mouse (70), suggesting that Tyk2 may play an inhibitory role in
maintenance of skeletal muscle progenitors. The role of Tyk2 needs to be further
explored with respect to what other genes does it control, how is it activated in response
to cold and what other proteins it interacts with.
Therapies for obesity include increasing energy expenditure by exercise and reducing
caloric intake. Unfortunately, only a small proportion of obese individuals are able to
maintain their reduced body weight on a diet and exercise regime. Bariatric surgery is
recommended for extreme obese patients, however it also comes with side effects (5).
As of today, FDA has approved three drugs for treatment of obesity which aim at
decreasing energy intake. Sibutramine and Phentermine act on the satiety centers in
the brain and thus control food intake by obese individuals. Orlistat reduces absorption
of fatty acids in the intestine (92). However, apart from the unpleasant side effects that
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these drugs possess, clinical studies on patients have shown that once the treatment is
stopped, weight gain is accelerated, thus limiting the success of these treatments.
Reducing caloric intake also triggers the starvation response in mammals, which may
also reduce the efficacy of these drugs.
The other promising treatment for obesity is increasing energy expenditure. Increasing
the thermogenic potential of brown fat and skeletal muscle could provide means to
increase energy wasting by these tissues, thus potentiating their anti-obesity effects.
However, increasing energy expenditure has to be maintained in a controlled manner. If
the inherent function of brown fat and skeletal muscle could be modified, which would
change the basal metabolic rate (BMR) of an individual, these effects would be
beneficial in the long run. In the 1930s, mitochondrial uncoupler 2, 4 dinitrophenol
(DNP) gained popularity as an anti-obesity drug. DNP, like UCP1, created a proton leak
in the mitochondrial membrane, thus dissipating the potential energy as heat. Although
DNP was successful in reducing obesity, continuous use of DNP generated unwanted
side effects including hyperthermia, which resulted in death in some cases. Hence,
when aiming to develop drugs that increase energy expenditure, careful considerations
about not expending excessive energy should be taken into account. If a balance
between energy intake and expenditure could be maintained, that will be a better way to
combat obesity.
Given the role of Tyk2 in regulating function of brown fat and skeletal muscle, controlled
activation of Tyk2 to improve the energy expenditure in these thermogenic tissues could
provide an attractive therapy for treatment of obesity.

111

Figure 4.1: Tyk2 may be required for the commitment of Myf5+ progenitors: Tyk2
may be required along with PRDM16 for commitment of Myf5+ mesenchymal stem cells
towards brown adipocytes and may also play an inhibitory role in commitment of the
Myf5+ cells towards skeletal muscle development.
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Figure 4.2: Tyk2 regulates genes involved in BAT and SKM differentiation and/or
function: Tyk2 may be a part of a multiprotein transcriptional complex regulating genes
involved in BAT and SKM differentiation/function.
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